3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Ovarian Neoplasms
101
Endometrial Neoplasms
74
Uterine Cervical Neoplasms
63
Carcinoma, Non-Small-Cell Lung
56
Colorectal Neoplasms
50
Melanoma
49
Triple Negative Breast Neoplasms
42
Carcinoma, Renal Cell
41
Stomach Neoplasms
37
Squamous Cell Carcinoma of Head and Neck
35
Fallopian Tube Neoplasms
33
Breast Neoplasms
33
Pancreatic Neoplasms
27
Neoplasms
25
Esophageal Neoplasms
24
Carcinoma, Transitional Cell
24
Neoplasm Metastasis
23
Carcinoma, Hepatocellular
20
Lung Neoplasms
19
Carcinoma, Ovarian Epithelial
19
Small Cell Lung Carcinoma
18
Head and Neck Neoplasms
18
Urinary Bladder Neoplasms
17
Parkinson Disease 4, Autosomal Dominant Lewy Body
17
Prostatic Neoplasms
14
Cholangiocarcinoma
13
Carcinoma, Merkel Cell
11
Kidney Neoplasms
10
Mesothelioma
9
Uterine Neoplasms
8
Interventions
Blood Specimen Collection
3
pembrolizumab
1
atezolizumab
1
TKM-080301
1
TIC10 compound
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
RNA, Long Noncoding
1
Interviews as Topic
1
Interleukin-15
1
HIV Testing
1
Educational Status
1
Diffusion Magnetic Resonance Imaging
1
Diffusion
1
CA-125 Antigen
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease
×
pembrolizumab
×
Gynecologic
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled